menu
    • menu
    [{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Sirtex"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"The Australian Research and Development Tax Incentive","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ The Australian Research and Development Tax Incentive","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ The Australian Research and Development Tax Incentive"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"Providence Cancer Institute","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Tavokinogene Telseplasmid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Providence Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Providence Cancer Institute \/ OncoSec","highestDevelopmentStatusID":"6","companyTruncated":"Providence Cancer Institute \/ OncoSec"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Sirtex"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OncoSec Immunotherapies \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Immunotherapies \/ National Institute Health"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tavokinogene Telseplasmid

    Menu

    Tavokinogene Telseplasmid

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

                            Details : Tavo works by optimizing cellular uptake of DNA-based IL-12 recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity.

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 02, 2021

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress...

                            Details : KEYNOTE-695 is OncoSec's registration-directed Phase 2b trial evaluating TAVO, a DNA plasmid-based interleukin-12 (IL-12) + KEYTRUDA® (pembrolizumab) in patients with rigorously confirmed anti-PD-1 checkpoint resistant metastatic melanoma.

                            Brand Name : TAVO

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 15, 2021

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12

                            Details : The CORVax12 vaccine approach combines the co-administration of OncoSec’s TAVO with a DNA-encodable version of the SARS-CoV-2 spike glycoprotein to boost the immunogenicity of the component developed by NIAID Vaccine Research Center scientists.

                            Brand Name : CORVax12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 27, 2021

                            Lead Product(s) : SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sirtex Medical

                            Deal Size : $30.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

                            Details : Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sirtex Medical

                            Deal Size : $30.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its G...

                            Details : The applications are directed to the use of OncoSec's interleukin-12 (IL-12)-based immunotherapy platform, including its lead product candidate TAVO™ delivered with the Company's proprietary intratumoral gene electrotransfer system for the treatment of...

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 10, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic ...

                            Details : OncoSec will present new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAVO™ in combination with KEYTRUDA® in patients with anti-PD-1 checkpoint refractory metastatic melanoma at 35th SITC Annual...

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 03, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Va...

                            Details : CORVax12 is the first next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity.

                            Brand Name : CORVax12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform

                            Details : Patent covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a partic...

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 06, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Starts a Phase 2 Study at the Moffitt Cancer Center to Evaluate Combination of TAVO plus OPDIVO® as N...

                            Details : Anti-PD-1 immune checkpoint therapies, such as OPDIVO®, are an established first-line treatment for advanced melanoma, and encouraging clinical data suggest that they have clinically meaningful activity in the neoadjuvant setting as well.

                            Brand Name : Tavo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 27, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            OncoSec Immunotherapies

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AAC...

                            Details : OncoSec Medical Incorporated presented new data further demonstrating the power of OncoSec's next-generation IL-12 plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9).

                            Brand Name : Tavo plus

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 22, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth